What the Study Found (In Plain English)
Published in American journal of kidney diseases : the official journal of the National Kidney Foundation (2001), this randomized controlled trial evaluating 1,715 human participants investigated: A prospective, randomized, three-armed, double-blind, placebo-controlled clinical trial has been completed in 210 sites worldwide to determine whether the angiotensin II receptor blocker irbesartan or the calcium channel blocker amlodipine has a renoprotective effect in patients with overt type 2 diabetic nephropathy. Key clinical takeaway: This large-scale international trial should help define the clinical course and standards of care for hypertensive adults with type 2...
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (American journal of kidney diseases : the official journal of the National Kidney Foundation, 2001-10-15; N = 1715; Rigor 96/100): This large-scale international trial should help define the clinical course and standards of care for hypertensive adults with type 2 diabetes mellitus and nephropathy.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.